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ABSTRACT 
It is essential to guarantee physico-chemical compatibility between the active pharmaceutical ingredient (API) and the components 
that are planned to be used in the development of a pharmaceutical formulation. A successful compatibility study allows 
distinguishing between the excipients that can be used and those that may represent a risk in the quality, safety and efficacy of the 
medication. The present study focuses on the identification of possible incompatibilities between Rupatadine fumarate and the 
excipients of three formulation prototypes for the development of API´s 10 mg tablets. Samples of each raw material, placebos and 
preformulation mixtures were analyzed by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), X-ray 
diffraction (XDR) and infrared spectroscopy (IRS). The results obtained were analyzed and contrasted with the literature. Based on 
these, it is demonstrated that the excipients used along with the API do not generate problems in terms of compatibility, as there are 
no chemical changes in the drug. 
Key words: Active pharmaceutical ingredient, Chemical incompatibility, Compatibility study, Differential scanning calorimetry, 
Infrared spectroscopy, Preformulation powder mixtures, Rupatadine fumarate, Thermal analysis, Thermogravimetric analysis, X ray 
diffraction. 
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INTRODUCTION  
It is mandatory to investigate the different fundamental 
physical and chemical properties of a drug, as well as the 
excipients that are planned to be used in the design of a 
product. This initial phase is known as “preformulation”, 
and base on its findings it is intended to design a 
pharmaceutical form that guarantees quality, safety and 
efficiency from early stages, by anticipating possible 
problems that may arise during the formulation process 
and that may lead to a risk in the stability of the 
medication. 1 
Compatibility studies within the pharmaceutical 
preformulation process consist in the evaluation of the 
drug in the presence of those excipients that are expected 
to be incorporated in the pharmaceutical form. 
Therefore, it is intended to detect in a relatively short 
period of time, possible physicochemical interactions or 
incompatibilities between the excipients and the active 
pharmaceutical ingredient (API), in order to avoid the 
formation of degradation products in the pharmaceutical 
form. 2, 3 
Stability prediction methods under accelerated 
conditions, like isothermal stress through a stability 
chamber, require long periods of time and also specific 
methods of analysis for both, the API and the 
degradation products. Given the above, there are other 
methods for the conduction of solid compatibility studies 
that are available for the researcher, such as the thermal 
analysis. 4, 5, 6 
Differential Scanning Calorimetry (DSC) and 
Thermogravimetry (TGA) are techniques that allow the 
thermal characterization of the raw materials of interest, 
as well as a quick and preliminary identification of 
possible interactions or physicochemical 
incompatibilities that occur between the API and the 
excipients. 6, 7 
To carry out a compatibility study, it is necessary to 
prepare mixtures of the components that are subject of 
the study. The formulator is able to analyze binary 
mixtures or the matrix, in order to determine interactions 
between the components of interest that can result in a 
physical and/or chemical change. The way in which 
these physical mixtures are prepared will depend on the 
scope wished for the study. In many cases, mixtures in a 
1:1 ratio may represent an enormous stress for the 
components which is not going to be reached according 
to the design established during the formulation stage. 
Therefore, for drug development, several authors 
support the utility of evaluating the compatibility 
between the components of a formulation, through the 
preparation of mixtures that contain all of them in the 
real proportion in which they will be found in the 
pharmaceutical form. 8, 9 
The API involved in the present compatibility study is 
Rupatadine fumarate (see figure 1), its IUPAC 
nomenclature is 8-chloro-6, 11-dihydro-11- [1- [(5-
methyl-3-pyridyl) methyl] -piperidin-4-ylidene] -5H-
benzo [5,6] cyclohepta [1,2-b] pyridine fumarate. The 
compound constitutes a potent selective second 
generation antihistamine of the H1 receptor, reason why 
it is widely used in the symptomatic treatment of allergic 
rhinitis and urticaria in adults and children older than 12 
years, with a daily dose of 10 mg. 10 ,  11, 12, 13 
 
Figure 1: Chemical structure of Rupatadine fumarate. 
For the execution of the present compatibility study, the 
analysis of placebo samples and mixtures that include 
the API will be done through techniques such as DSC, 
TGA, Infrared spectroscopy (NIR) and X ray diffraction 
(XDR). The results of the preformulation mixtures and 
placebos will be compared between them and with the 
analysis made to raw material individually, in order to 
determine if there are any modifications that cause an 
alteration of the physicochemical stability of the 
mentioned mixtures under study. 
MATERIALS AND METHODS 
Raw materials used for the research were provided by a 
national industry. For the execution of this study it was 
decided to evaluate the compatibility between excipients 
and active pharmaceutical principle, according to the 
three formulation prototypes that are shown in the table 
2, where a check means that the component is present 
and X means that it is not included 
 
Table 1: Materials used for the research 
 
Raw materia Manufacturer 
Rupatadine fumarate Enaltec laboratories India, batch No. EL-03/L095/16025. 
Monohydrate lactose (Supertab® 11SD) DFE Pharma, batch No. 1010KX2. 
Microcrystalline cellulose (Pharmacel® 102) DFE Pharma, batch No. 100202. 
Sodium croscarmellose JRS Pharma, batch No. 7111512407. 
Pregelatinized starch (Superstarch® 200) DFE Pharma, batch No. 10069PO. 
Magnesium stearate Helianthus, batch No. MGSV150475. 
Stearic acid BTP Pharma, batch No. 20150620. 
PVP K-30 Ashland, batch No. 0001855552 
 Castillo et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2018; 8(3):42-54            
ISSN: 2250-1177                                                                               [44]                                                                              CODEN (USA): JDDTAO 
Table 2: Qualitative composition of the preformulation mixtures 
Raw materia Formula 1 (%) Formula 2 (%) Formula 3 (%) 
Rupatadine fumarate ✔ ✔ ✔ 
Monohydrate lactose ✔ ✔ ✔ 
Microcrystalline cellulose ✔ ✔ ✔ 
Sodium croscarmellose ✔ ✔ X 
Pregelatinized starch X X ✔ 
Magnesium stearate ✔ ✔ X 
Stearic acid X X ✔ 
PVP K-30 X ✔ X 
 
Initially, raw materials were sieved using a mesh 20. 
After that, both, placebo mixtures and the ones with the 
API were prepared in the real proportion according the 
prototype. Five grams samples of each powder mixture 
were taken randomly and transferred to the test site 
under controlled conditions of temperature, light and 
humidity. The conditions and specifications of the 
equipments used are: 
Differential Scanning Calorimetry 
 Equipment  
 DSC TA Instruments model Q200. 
Conditions 
 Aluminum capsule. 
 100% Nitrogen Atmosphere 10 psi. 
 Flowrate: 40 mL / minute. 
 Heating series: isotherm at 20°C for 5 minutes, then 
increase 10 ° C / minute. 
 Temperature range: 20 ° C to 250 ° C. 
 Sensitivity Instrument and Recorder: Sensitivity 0.1 
uW. 
 Temperature precision: ± 0.05 °C. 
 Temperature accuracy: ± 1 °C. 
 Calorimetric precision: ± 0.1%. 
 Calorimetric reproducibility: ± 0.1%. 
 Weight: 4 to 5 mg sample. 
 Calibration with Indium and distilled water.  
 Three replicas. 
Thermogravimetric Analysis  
Equipment 
 TGA TA Instruments model Q500. 
Conditions 
 100% Nitrogen 10 psi Atmosphere. 
 Volume flow: 40 mL / minute. 
 Heating rate: 10 ° C / minute. 
 Temperature range: 20 °C to 1000 °C. 
 Weight: 4 to 5 mg sample. 
 Sensitivity: 0.1 ug. 
 Isothermal temperatura accuracy: ± 0.1%. 
 Isothermal temperature precision ± 0.1%. 
 Three replicas. 
Infrared Spectroscopy 
Equipment 
 FTIR Thermo Scientific Nicolet model 6700. 
Conditions 
 Range: 600 to 4000 cm-1. 
 Temperature: 25 °C. 
 Relative humidity: 30%. 
 200 scans per replica. 
 Three replicas. 
X ray Diffraction  
Equipment 
 Diffractometer: PANalytical Empyrean. 
Conditions 
 Temperature: room temperatura 25 °C. 
 Nickel filter. 
 Copper anode source Kα (λ 1, 54 A°). 
 Polymethacrylate sample holder. 
 Continuous analysis at 0.1° per second in the range 
of 3° to 40 ° 2θ. 
 Gas detector with photodiodes. 
 Weight: 10 to 15 mg sample. 
 Three replicas.  
RESULTS 
The current investigation studies chemical compatibility 
between de API, Rupatadine fumarate, and the 
excipients used in three preformulation mixtures, by 
making a comparison between the results obtained 
through different tests applied to the samples, and 
physicochemical parameters reported on literature and 
patents. Those results were used to make conclusions 
about the compatibility of the API with the excipients 
that can be used in an eventual successful formulation.  
Differential Scanning Calorimetry 
Figure 2 shows the results of the thermal analysis made 
to the samples of Rupatadine fumarate raw material, 
through DSC. The thermogram presented shows an 
endothermic event at 201.28 ºC which corresponds to 
the melting point of the substance. Likewise, a 
decomposition of the sample is visible after the melting, 
and it is shown as a transition to an exothermic event 
around 208 ºC. The mentioned melting and 
decomposition occurs in a narrow range of temperature. 
There are no other thermal events related with any other 
decomposition, surface water loss or impurities before 
the melting point. 
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Figure 2: Thermal analysis of Rupatadine fumarate through DSC 
 
Figure 3 shows the results of the thermal analysis made 
to the excipients used for the samples of the placebos 
and formulas, through DSC. Based on the thermogram, 
it is possible to see the following melting points: 
Monohydrate lactose 218.21 °C, croscarmellose 87.63 
°C, magnesium stearate 80.48 °C and 115.83 °C, 
microcrystalline cellulose 72.44 °C, pregelatinized 
starch 78.35 °C, stearic acid 58.15 °C and povidone 
88.88 °C. 
 
 
Figure 3: Thermal analysis of the excipients through DSC 
 
Figures 4 - 6 show a comparison of the DSC analysis 
between the API, placebo and its corresponding formula. 
According to this methodology, it is possible to notice 
that every thermogram shows similarities in the placebo 
and formula behavior, but the most important thing is 
that there are no new exothermic peaks and the 
temperature at which the melting of the API occurs in 
the formula is pretty close to the one of the substance 
alone. Also, it can be seen that most of the melting or 
endothermic peaks of the excipients are missing. 
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Figure 4: Comparison of the thermal analysis between 
API, placebo 1 and formula 1 through DSC 
 
Figure 5: Comparison of the thermal analysis between 
API, placebo 2 and formula 2 through DSC 
 
Figure 6: Comparison of the thermal analysis between 
API, placebo 3 and formula 3 through DSC 
Thermogravimetric Analysis 
In order to analyze the results, the thermograms shown 
were divided in three stages: 1) 0 - 150 °C, 2) 150 - 400 
°C and 3) 400 - 1000 °C. However, thermal events that 
take place above 300 °C are not considered relevant for 
this analysis. 
Figure 7 shows the thermogravimetric analysis of 
Rupatadine fumarate raw material from Enaltec 
Laboratories. It can be seen that there´s no mass 
decrease in the first stage. The analysis of the second 
stage showed about 20% of mass decrease between 205 
°C - 208 °C and 75 % around 300 °C. It is relevant to 
say that the test allowed to evaluate and prove sample´s 
purity, as there were any decomposition events or mass 
losses linked with residual solvents or related 
substances, present in raw material. 
  
  
Figure 7: TGA of Rupatadine Fumarate 
Figures 8 - 10 show a comparison of the 
thermogravimetric analysis between the API, placebo 
and its corresponding formula. Based on the mentioned 
methodology, the thermograms reveal a similar behavior 
below 300 °C between the placebo and its formula. The 
thermograms show a mass loss at a temperature below 
210 °C. Also, they exhibit another mass loss between 
280 - 300 °C, and that event is in agreement with the 
API's individual thermogravimetric analysis. In the 
second stage, the mass loss in the placebos and its 
corresponding powder formula for prototypes 1 and 2, 
constitutes between 67 - 68% of the sample. On the 
other hand, regards to prototype 3, it is possible to 
interpret from the thermogram represented in figure 10, 
a mass loss of 73 % for the placebo and 71% for the 
formula.
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Figure 8: Comparison of the thermal analysis between API, placebo 1 and formula 1 through TGA 
 
Figure 9: Comparison of the thermal analysis between API, placebo 2 and formula 2 through TGA 
 
 
Figure 10: Comparison of the thermal analysis between API, placebo 3 and formula 3 through TGA 
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Infrared Spectroscopy 
According to the API´s infrared spectrum presented in 
figure 11, it is possible to identify the characteristic 
bands of this molecule in the infrared spectrums of the 
three formulas, as it can be seen in figures 12 – 14. The 
identification and interpretation of each characteristic 
band is presented in table 3. 
   
 
Figure 11: Infrarred spectroscopic analysis of Rupatadine Fumarate 
 
 
Figure 12: Comparison of the infrared spectroscopic analysis between API, placebo 1 and formula 1 
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Figure 13: Comparison of the infrared spectroscopic analysis between API, placebo 2 and formula 2 
 
 
Figure 14: Comparison of the infrared spectroscopic analysis between API, placebo 3 and formula 3 
 
Table 3. IR bands interpretation. 
Wave number 
(cm-1) 
Interpretation 
Wave number 
(cm-1) 
Interpretation 
2987,41 C-H stretching of alkanes and aromatic rings. 1420,6 O-H splitting of carboxylic acids. 
1698,71 C=O stretching. 1327,5 C-N stretching of aromatic amine. 
1593,7 
N-H splitting of an amino group and C=C 
stretching of an alkene cycle. 
1205,55 
C-N stretching of an amino 
group. 
1437,39 C-H splitting of an alkane (methyl) group. 
830,88 and 
781,72 
C-Cl stretching and vibration. 
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X Ray Diffraction 
Figure 15 shows the results obtained through the 
analysis of the Rupatadine fumarate samples with X ray 
diffraction. The mentioned figure represents a classic 
pattern of a crystalline substance. In a previous 
investigation, we confirmed that this molecule hasn´t 
any other polymorphic forms besides A form, same as it 
is established in the literature. 14, 15 
This crystalline form exhibits two principal peaks, the 
first one around 20 2θ and the second one is near 25 2θ. 
Even though, there are four other peaks of lower 
intensity around 13, 17, 21 and 23 2θ, they are still 
relevant for the characterization and identification of the 
crystalline form. The placebos samples show 
characteristic peaks of each crystalline component 
included. It is important to highlight that the 
diffractogram of each formula shows both, the peaks of 
the API, as well as the excipients contained in the 
corresponding placebo, as it can be seen in figures 16 - 
18.
 
 
Figure 15: X-ray diffractometry of Rupatadine fumarate 
 
Figure 16: X-ray diffractometry comparison between API, placebo 1 and formula 1 
 
 
Figure 17: X-ray diffractometry comparison between API, placebo 2 and formula 2 
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Figure 18: X-ray diffractometry comparison between API, placebo 3 and formula 3 
 
DISCUSSION 
Thermal Analysis 
The analysis of the matrix or the corresponding placebo 
for each formula is based on the principle that states that 
thermal properties of mixtures will be quite approximate 
to the sum of the thermal properties of each component 
individually, assuming that there are no interactions 
between the excipients and the API.16 
According to the results of the API’s DSC analysis, it is 
possible to determine if it interacts chemically with the 
excipients that are present in the preformulation 
mixtures, based on the peaks that are shown in the 
thermograms, but most important related with the 
changes that may occur to the melting point of the 
substance. For the formulas of interest, the existence of 
an incompatibility was considered when the 
thermograms show a disappearance or widening of the 
API´s fusion endotherm. 5 
In the DSC analysis, it is possible to notice that the 
samples corresponding to the prototype 3, placebo and 
formula, differ from the mixtures of the other two 
prototypes, because they present an endothermic event 
around 57 °C and 59 °C, respectively. It is important to 
highlight the presence of stearic acid as a lubricating 
agent in prototype 3. Indeed, the peaks at the mentioned 
temperatures can be explained due to this excipient. The 
melting point of the component varies depending on its 
composition and purity, so according to various studies 
it has been observed that the fusion can occur between 
50 - 70 °C. Figure 3 shows the calorimetric curve of 
stearic acid, which indicates that for the sample in 
question, the fusion according to the DSC analysis 
occurs at 58.15 °C. 6, 17 
Pregelatinized starch is the other compound that is 
included only in this prototype. Its thermogram found in 
the literature shows an extensive endotherm between 60 
°C and 140 °C due to water loss. It can be observe in the 
DSC analysis shown in figure 3, an endotherm for the 
excipient that occurs between 43.23 °C and 111.62 °C. 5, 
18 
With the exception of the previously exposed situation 
regarding stearic acid, it is possible to observe that all 
the analysis of placebos and formulas by DSC follow a 
common pattern, in which the different events that can 
be identified show similar values in terms of enthalpy. 
The analysis of the curves depicts an extensive 
endotherm below 100 °C, characteristic of the loss of 
absorbed moisture. In addition, it can be observed 
around 145 °C that there is an endothermic event, which 
is explained by the dehydration of monohydrate lactose, 
as it follows the same behavior shown by the excipient 
in figure 3. This event has been widely reported in the 
literature at temperatures around 144.47 °C. The 
manifestation of the event at that temperature and not at 
100 °C can be justified by the fact that since the waters 
are incorporated intramolecularly, the energy required to 
break the existing bonds must be greater. 5, 19 
For magnesium stearate, literature establishes a first 
endothermic peak that occurs between 84 -97 °C, 
corresponding to its dehydration. It can be seen in figure 
3 that this first event occurs at 80.48 °C. Also, a second 
endothermic event is presented at 115.83 °C, which 
according to the literature, it occurs between 112 - 121 ° 
C and is linked to the fusions of its constituent fatty 
acids. 7 
Regarding sodium croscarmellose, studies report an 
extensive endothermic peak from 56 °C to 
approximately 117 °C, as a result of water loss. Figure 3 
shows how that behavior is reflected in the analysis 
performed, since the endotherm occurs from 52.53 °C to 
123.82 °C. For another excipient, microcrystalline 
cellulose, literature indicates the existence of an 
endotherm from 57.5 °C to 124.7 °C, while the analysis 
revealed that it occurs between 43.23 °C to 108.69 °C. 
In the case of povidone its melting point varies 
according the complexity of the polymer, showing in 
this case an endotherm that begins at 58.0 °C and its 
endpoint occurs at 114.31 °C. 7, 20, 21 
Nevertheless, in spite of what literature establishes and 
the results presented in figure 3; the following 
excipients did not show significant thermal events in the 
analysis of placebos or formulas within the temperature 
range used: Pregelatinized starch, sodium 
croscarmellose, microcrystalline cellulose, magnesium 
stearate and povidone. The identification of the thermal 
events corresponding to each raw material is difficult to 
differentiate in these samples, because the components 
are present at least ten times lower compared to its 
individual analysis, with the only exception of 
microcrystalline cellulose which is present around 30 % 
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in the three prototypes. In addition, such a fact can also 
be explained due to the overlap with the rest of events 
occurring along to the temperature range worked, where 
the thermogram is governed mainly by the thermal 
behavior of the lactose monohydrate, since it is the 
diluent and therefore, the excipient present in a greater 
proportion. 5, 18 
On the other hand, literature indicates that the melting 
point of the fumarate salt present in the formulas is 
around 197 - 201 °C and according to the analysis 
presented in figure 2, the active pharmaceutical principle 
has a melting peak at 201.38 °C. It can be observed in 
the calorimetric curves of figures 4 - 6 relative to the 
formulas, that the melting point decreases around 197.16 
°C for formula 1, 195.94 °C for formula 2 and 195.48 
°C for the third formula. It is important to emphasize 
that the API melts with decomposition, which implies 
that the temperature necessary to occur the 
decomposition of the drug is very close to its melting 
point. In all three cases there is evidence of 
decomposition, at approximately 201 °C, although this 
event is practically overlapped with the endotherm 
corresponding to the start of the fusion of lactose. 10, 19 
The analysis carried out by TGA allowed the 
measurement of the thermal stability of raw materials, 
the determination of the moisture content and / or 
solvents, and together with the DSC, it backs up the 
results obtained by each other. The method allows 
illustrating the thermal transitions of a material, where a 
mass loss occurs with each thermal event, which implies 
the volatilization of one or more components. With this 
technique it is only possible to detect chemical 
reactions, since physical changes such as fusion, do not 
imply a mass loss. 22 
According to the temperature division previously 
established in the results section, it can be said regarding 
to the TGA of the API (see figure 7), the lack of mass 
loss in the first stage of the thermogram can be 
interpreted as no loss of surface water, neither as 
decomposition events in that temperature range. It can 
also be explained by the lack of hydrates associated to 
the crystal. The behavior of the sample at this stage 
confirms what is shown by the thermogram of figure 2. 
However, the second stage showed 20% of mass 
decrease between 205 - 208 °C, which matches with a 
first decomposition event of the API and it is also in 
agreement with the decomposition temperature obtained 
by the differential scanning calorimetry analysis of the 
sample. Then, around 300 °C it is possible to appreciate 
a second and greater decomposition which is the 
responsible of the 75 % loss of the mass sample. 8, 10, 11 
The thermogravimetric analysis carried out on the 
placebos and the formulas showed in the first stage, 
approximately before 140 °C a mass loss that does not 
exceed 5% of the sample. This confirms the dehydration 
of the monohydrated lactose, as well as the evaporation 
of the water absorbed by the rest of the components. 23, 
24 
It is important to emphasize that literature reports three 
characteristic mass losses for lactose. Figure 19 
exemplifies the three events in question, where the first 
decrease in mass of the sample occurs between 40 °C 
and 130 °C, corresponding to the loss of absorbed water. 
The second one occurs between 130 - 150 °C, and is due 
to the loss of the water of crystallization. Finally, when 
reaching 300 °C there is a continuous mass loss due to 
its decomposition. 21, 23 
 
 
Figure 19: Thermogravimetric analysis of lactose monohydrate. (23) 
 
Likewise, when comparing DSC and TGA thermograms 
corresponding to prototype 3, it can be verified that 
indeed, the endotherm observed between 55 and 57 °C 
in the DSC, corresponds to the fusion of stearic acid, 
since the TGA doesn´t show thermal events related to a 
mass loss that could indicate a decomposition event at 
that temperature. 
Also, the mass loss at 200 °C in the TGA of the 
formulas reveals a decomposition of the API, which is in 
appearance according to the first decomposition event 
showed by the DSC analysis. Furthermore, for those 
samples the second mass loss between 280 - 300 °C is in 
agreement with the API's individual thermogravimetric 
analysis. Such loss of mass can be accompanied by other 
excipients decomposition such as sodium 
croscarmellose, magnesium stearate and povidone. After 
this event, all samples still have more than 79% of the 
initial mass. At higher temperatures the cellulose begins 
its decomposition process between 285-350 °C, which 
also occurs along with a depolymerization processes. 
The sodium croscarmellose maintains a decomposition 
that can extend up to 600 °C. 24, 25, 26 
Infrarred Spectroscopy 
For the purposes of the present investigation, IRS was 
used as it studies the absorption of energy by functional 
groups of the molecules that constitute the sample and is 
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conceived as an extra method of corroboration of the 
compatibility results thrown by the DSC and TGA. 27 
It should be noted according to what is presented in 
figures 11 – 14, that the bands identified for the API (see 
figure 11) can be found in powder formula mixtures (see 
figures 12 - 14), so it is considered that there has not 
been any chemical change related to the drug. 
X Ray Diffraction 
This non-destructive analytical technique provided 
detailed information about the internal arrangement of 
the crystalline substances in study. The analysis by XDR 
of the API did not reveal any differences in contrast to 
what is established in the literature, which indicates that 
the characteristic peaks for the polymorph A of the 
fumarate salt (only crystalline form reported) are: 11.6; 
12.5; 13.6; 14.9; 15.5; 16.1; 16.6; 17.0; 18.1; 19.6; 20.2; 
21.3; 22.2; 23.1; 23.6; 24.3; 24.8; 25.4; 25.8; 26.8; 27.6; 
28.5; 28.8; 30.6; 32.7; 33.2; 34.6; 36.2; 36.8 and 37.9. 
The following diffractogram represents the peaks 
corresponding to the pattern, whose purity is 99.5%.
 
 
Figure 20: XDR analysis of the fumarate salt standard according to the literature. 15 
 
Similarly, the analysis corresponding to the powder 
formula did not reveal any alteration in the crystalline 
arrangement of the API, neither the excipients in 
question, as can be seen in figures 15 - 18. It´s important 
to clarify that the intensity of the peaks corresponding to 
the drug, decreases in those analysis, since its 
concentration is much lower. 
CONCLUSIONS 
Although the thermal analysis results of the formulas 
show slight deviations in terms of melting temperature 
of the API, it is important to remember that DSC and 
TGA provide an approximate overview of the chemical 
and physical behavior of the formula, so they are 
methods used in a preliminary way to determine or rule 
out incompatibilities. 
At the moment of carrying out analysis in the way 
previously described, it should be taken into 
consideration that multiple interactions may occur, 
which can cause a decrease in the melting temperature of 
the API. However, not all solid-solid interaction detected 
implies a chemical instability, that´s because they can 
also be linked to the technological process used in 
manufacturing or to the proportion to which the API is 
present within the formulas. Therefore, the findings 
should be confirmed with another tool or method such as 
FTIR or HPLC, which will allow to definitively identify 
whether or not chemical incompatibility exists. 
Following the results of the thermal analysis, it is 
preliminarily considered that the three formulas 
proposed are potential candidates for the development of 
a pharmaceutical product, since no significant chemical 
incompatibilities were detected between the API and the 
excipients. This situation is strongly supported by the 
results obtained through the XDR analysis and mainly 
by IRS, where no changes were detected for the 
molecule of the API. 
However, based on the small changes in the melting 
point of the active pharmaceutical ingredient in the 
formulas, as well as in the composition of these, it is 
important to emphasize the extensive history of 
incompatibilities caused by magnesium stearate and 
stearic acid. In spite of the above and in case of 
confirmation of such fact, it is necessary to establish a 
criterion to determine if the incompatibility is really 
significant and implies a true risk for the quality, safety 
and efficacy of the medication. 
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